Patented Medicine Prices Review Board
Add to list
The Patented Medicine Prices Review Board (French: Conseil d'examen du prix des médicaments brevetés) is a federal quasi-judicial regulatory and reporting agency in Canada with a mandate to protect consumers by ensuring that the prices of patented medication charged by manufacturers of patented drugs are not excessive. The board does this through its role as a regulator, and through its reporting on trends, research and development in the Canadian pharmaceutical industry.
The board investigates, reviews and negotiates the price of individual drugs that are still under patent and which have no generic substitutes. It establishes the maximum prices that can be charged in Canada for patented drugs.
Médicaments génériques au Canada, 2013 : Generic drugs in Canada, 2013
11 Dec 2014
Generic drugs in Canada, 2013 : Médicaments génériques au Canada, 2013
11 Dec 2014
Utilization of prescription opioids in Canada's public drug plans, 2006/07...
23 Apr 2014
Les facteurs de coût associés aux dépenses en médicaments d'ordonnance -...
13 Dec 2013
The drivers of prescription drug expenditures - a methodological report :...
13 Dec 2013
Analytical snapshot : International generic price comparison, early 2011
27 Aug 2013